葡萄糖样-1受体激活剂用于关节炎和骨关节炎
1Nursing and Midwifery Research, Hamad Medical Corporation, Doha, QAT.
Cureus
|October 30, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 通过减少炎症和帮助减肥,为关节炎提供潜在的益处. 然而,它们也可能增加痛风发作和关节疼痛,需要对个体患者进行仔细考虑.
科学领域:
- 内分泌学和新陈代谢学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是针对2型糖尿病 (T2DM) 和肥胖的已知治疗方法.
- 它们在关节炎管理中的作用仍在调查中,呈现出复杂的临床情况.
研究的目的:
- 探索GLP-1RAs对各种形式关节炎的多方面的影响.
- 分析与GLP-1RA在关节炎疾病中的使用相关的潜在益处和风险.
主要方法:
- 对GLP-1RAs及其对炎症标志物,关节健康和体重的影响现有文献的综述.
- 分析报告的副作用,包括痛风发作和关节疼痛.
主要成果:
- GLP-1RAs可能会带来诸如减少全身炎症,减肥引起的关节应激减轻和冠状动脉保护等益处.
- 潜在的不良影响包括痛风发作和关节疼痛的发生率增加,长期结果不确定.
结论:
- GLP-1RAs在关节炎中具有双重效应特征,在显著风险的同时提供潜在的治疗优势.
- 治疗决策必须是个性化的,考虑特定的关节炎亚型和患者个人资料,以平衡好处和风险.
相关概念视频
Glucagon-like Receptor Agonists
832
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
832
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
513
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
513
Oral Hypoglycemic Agents: Biguanides and Glitazones
571
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
571
Oral Hypoglycemic Agents: Glinides
585
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
585
Dipeptidyl Peptidase 4 Inhibitors
574
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
574
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
423
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
423


